DA Davidson analyst Linda Bolton Weiser maintains WD-40 (NASDAQ:WDFC) with a Neutral and lowers the price target from $277 to $238.
Akoya Biosciences To Partner With Acrivon Therapeutics For The Clinical Development Of Acrivon’s Proprietary OncoSignature Test Into A Companion Diagnostic
Akoya Biosciences, Inc., (NASDAQ:AKYA), The Spatial Biology Company®, and Acrivon Therapeutics, Inc., a clinical-stage oncology therapeutics company with proprietary technologies driving a new era of precision-based
